Trial Profile
AERIAL: Changes in Health and Functional Status in Patients With COPD During Therapy With Spiolto Respimat
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms AERIAL
- Sponsors Boehringer Ingelheim
- 28 Mar 2019 Status changed from active, no longer recruiting to completed.
- 12 Feb 2019 Planned End Date changed from 31 Jan 2019 to 28 Feb 2019.
- 16 Nov 2018 Planned End Date changed from 18 Jan 2019 to 31 Jan 2019.